News  >  Breaking News  >  Hangzhou's Venus Medtech Acquires InterValve of the US

Hangzhou's Venus Medtech Acquires InterValve of the US

By Editing NAI
06/18/2017 5:28 a.m.

Venus Medtech of Hangzhou has acquired InterValve, a US maker of transcatheter aortic valve devices, the V8 and TAV8. Venus described the products as the world's pioneering aortic valvuloplasty balloon catheters with anatomical shapes. Balloon aortic valvuloplasty products widen a stenotic aortic valve using a balloon catheter inside the valve. The terms of the agreement were not disclosed. In April of this year, Venus's VenusA-Valve was approved by the CFDA, the first TAVR device approved for use in China.

Source: ChinaBio Today



Comments

No Comments


Please to leave a comment.